Literature DB >> 17031816

Whole-body magnetization transfer contrast imaging.

Andreas Boss1, Petros Martirosian, Klaus Küper, Gerhard Fierlbeck, Claus D Claussen, Fritz Schick.   

Abstract

PURPOSE: To demonstrate the feasibility of whole-body magnetization transfer (MT) contrast imaging.
MATERIALS AND METHODS: Whole-body MT imaging was performed on eight healthy volunteers and five patients (mean age=40.5+/-17.8 years) with diagnoses of dermatomyositis (N=1), B-symptoms with suspicion of paraneoplastic disease (N=1), metastatic malignant melanoma (N=1), and multiple sclerosis (MS) (N=2). Measurements were carried out on a 1.5-Tesla whole-body MR scanner capable of parallel signal reception. A three-dimensional (3D) gradient-echo sequence (TR=17 msec, TE=4.8 msec, flip angle=10 degrees) was applied in combination with a Gaussian off-resonance MT preparation pulse acting at an off-resonance of 1.500 Hz with a 500 degrees effective flip angle. Whole-body images were constructed from five different body regions.
RESULTS: In all subjects, whole-body MT contrast images were obtained within less than 20 minutes of measuring time. The images showed sufficient diagnostic image quality to assess the patients' pathologies. The MT ratios (MTRs, in percent units) for the volunteers were as follows: white matter (WM) 51.1+/-1.0, gray matter (GM) 42.2+/-1.3, skeletal muscle (mean value of four muscle groups) 50.3+/-2.1, liver 39.4+/-3.2, spleen 31.8+/-2.6, renal cortex 30.4+/-1.9, and renal medulla 25.6+/-1.3. The MTRs for the pathologies were as follows: skeletal muscle in dermatomyositis approximately 30, metastases in malignant melanoma 30.7-36.0, uterus myoma 49.3, and MS lesions 30-40.
CONCLUSION: Our preliminary data indicate that MT contrast in whole-body MRI is feasible, and may be useful for rapid whole-body assessment of diseases that exhibit high contrast in MT imaging, such as MS and muscular disorders. Copyright (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 17031816     DOI: 10.1002/jmri.20754

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  6 in total

1.  Cross-sectional investigation of correlation between hepatic steatosis and IVIM perfusion on MR imaging.

Authors:  James T Lee; Joy Liau; Paul Murphy; Michael E Schroeder; Claude B Sirlin; Mark Bydder
Journal:  Magn Reson Imaging       Date:  2012-01-27       Impact factor: 2.546

2.  Influence of water compartmentation and heterogeneous relaxation on quantitative magnetization transfer imaging in rodent brain tumors.

Authors:  Ke Li; Hua Li; Xiao-Yong Zhang; Ashley M Stokes; Xiaoyu Jiang; Hakmook Kang; C Chad Quarles; Zhongliang Zu; Daniel F Gochberg; John C Gore; Junzhong Xu
Journal:  Magn Reson Med       Date:  2015-09-16       Impact factor: 4.668

3.  Magnetization transfer for the assessment of bowel fibrosis in patients with Crohn's disease: initial experience.

Authors:  Shila Pazahr; Iris Blume; Pascal Frei; Natalie Chuck; Daniel Nanz; Gerhard Rogler; Michael Patak; Andreas Boss
Journal:  MAGMA       Date:  2012-11-09       Impact factor: 2.310

4.  Quantitative magnetization transfer in in vivo healthy human skeletal muscle at 3 T.

Authors:  Christopher D J Sinclair; Rebecca S Samson; David L Thomas; Nikolaus Weiskopf; Antoine Lutti; John S Thornton; Xavier Golay
Journal:  Magn Reson Med       Date:  2010-07-27       Impact factor: 4.668

5.  Quantitative serial MRI of the treated fibroid uterus.

Authors:  Kirsty I Munro; Michael J Thrippleton; Alistair R W Williams; Graham McKillop; Jane Walker; Andrew W Horne; David E Newby; Richard A Anderson; Scott I Semple; Ian Marshall; Steff C Lewis; Robert P Millar; Mark E Bastin; Hilary O D Critchley
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

6.  Preliminary Application of Magnetization Transfer Imaging in the Study of Normal Uterus and Uterine Lesions.

Authors:  Qiu Bi; Qing Li; Jing Yang; Junyu Yang; Ji Du; Fan Ding; Yunzhu Wu; Shaoyu Wang; Ying Zhao
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.